Korea BNC (Korean BNC) has signed a five-year European distribution agreement with Nordberg Medical AB for its cross-linked hyaluronic acid (HA) and polynucleotide (PN) combination filler, JUVESELLE (formerly JUVEGEL). The deal, valued at approximately 57 billion KRW (about $43 million USD), grants Nordberg Medical exclusive rights to distribute the product across 41 European countries. This partnership signals a strategic push by Korea BNC to leverage Nordberg Medical's established European marketing and branding infrastructure, positioning JUVESELLE as a differentiated regenerative aesthetic filler in the competitive European market.
Deal structure and market scope
Korea BNC announced on the 16th that it is proceeding with a European distribution contract for JUVESELLE, a cross-linked HA and PN combination filler. The agreement spans five years and covers 41 European countries. The product will be launched under the European-exclusive brand name JUVESELLE. The contract value is approximately 570 billion KRW, reflecting the scale of the European market opportunity.
Partner profile: Nordberg Medical AB
Nordberg Medical, founded in 2016, is a global medical aesthetics company with reported sales exceeding 300 billion KRW across Asia and Europe, including affiliates. The company has successfully launched its PLLA-based product JULAINE in Europe and is expanding its footprint in regenerative aesthetics through academic marketing and branding capabilities. Nordberg Medical was a diamond sponsor at the 2026 AMWC Monaco exhibition and was a finalist in the 'Regenerative Aesthetic Solution' category at the 2026 AMWC Awards, underscoring its brand competitiveness in this segment.
Product positioning and strategy
JUVESELLE is a combination filler that cross-links HA with PN, offering a regenerative aesthetic concept distinct from traditional fillers. Korea BNC plans to leverage Nordberg Medical's European marketing infrastructure and network to enhance JUVESELLE's brand value. The strategy involves positioning JUVESELLE as a differentiated product in the European medical aesthetics market by integrating Nordberg Medical's branding capabilities. Both companies aim to combine their multinational clinical data and local marketing assets across the value chain to build a medical portfolio aligned with global regulatory guidelines.
What buyers should watch
For European distributors and clinics, this deal introduces a new regenerative aesthetic filler category combining HA and PN. The partnership leverages Nordberg Medical's proven track record in launching PLLA products and its strong academic marketing network. Importers should monitor regulatory approvals and clinical data supporting JUVESELLE's safety and efficacy. The product's positioning as a regenerative solution may appeal to clinics seeking differentiated offerings in the competitive European filler market.
Sourcing context
Korea BNC's decision to partner with a European distributor rather than entering the market independently reflects a common strategy among Asian OEMs to leverage local expertise for regulatory navigation and market access. The 5-year exclusive deal provides stability for both parties, while the 41-country coverage offers significant scale. Distributors should note that the product will be marketed exclusively under the JUVESELLE brand in Europe, potentially limiting parallel sourcing opportunities.
Source: Read the original report | Published: June 16, 2026